Fig. 2
![Fig. 2](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs40661-017-0047-8/MediaObjects/40661_2017_47_Fig2_HTML.gif)
AXAL planned phase III study. AXAL: axalimogene filolisbac; FIGO: International Federation of Gynecology and Obstetrics; GOG: Gynecologic Oncology Group; Q: quarter; UK: United Kingdom; US: United States
AXAL planned phase III study. AXAL: axalimogene filolisbac; FIGO: International Federation of Gynecology and Obstetrics; GOG: Gynecologic Oncology Group; Q: quarter; UK: United Kingdom; US: United States